Elevated PSA Levels: What They Mean & What Happens Next

What does an elevated PSA mean?

An elevated PSA means the prostate-specific antigen level in your blood is higher than expected for your age. PSA is a protein made by the prostate, and it rises with prostate enlargement, inflammation, infection, and cancer. A high result signals that the prostate needs evaluation — it does not identify the cause on its own.

PSA is organ-specific, not cancer-specific. That distinction is the source of nearly all the confusion around this test. The prostate makes PSA whether it is healthy, enlarged, inflamed, or malignant. A raised number tells you something is going on with the gland. It does not tell you what.

What is a normal PSA level by age?

There is no single normal PSA. The commonly cited 4.0 ng/mL cutoff is a historical convention, not a biological threshold — cancer occurs below it and benign conditions occur above it. Most urologists now interpret PSA against age-specific ranges, because the prostate enlarges naturally over time and produces more PSA as it does.

The age-specific reference ranges most widely used in practice (Oesterling ranges, representing the 95th percentile for healthy men):

A PSA of 4.2 ng/mL is unremarkable in a 72-year-old and warrants real attention in a 46-year-old. That is why the number by itself is close to meaningless without context.

Broad risk associations by PSA level, which apply to men who have already had benign causes ruled out:

These are population figures. Your individual risk depends on age, ethnicity, family history, prostate size, prior biopsy results, and what your PSA has been doing over time.

What causes a high PSA besides cancer?

Most elevated PSA results have a benign explanation. The most common are benign prostatic hyperplasia (BPH), prostatitis, and urinary tract infection. Several everyday activities and procedures also raise PSA temporarily, which is why timing matters and why a single result is rarely acted on alone.

Common benign causes:

• Benign prostatic hyperplasia (BPH) — age-related prostate enlargement. More tissue means more PSA. This is the single most common reason for a raised result. Learn about BPH →

• Prostatitis — inflammation or infection of the prostate, which can push PSA up dramatically and then back down after treatment

• Urinary tract infection — can elevate PSA substantially; testing should generally wait until the infection has cleared

• Recent ejaculation — can raise PSA modestly for up to 48 hours

• Vigorous cycling or horseback riding — pressure on the perineum can raise PSA for a day or two

• Recent urologic procedures — catheterization, cystoscopy, or a prostate biopsy can raise PSA markedly for weeks

• Digital rectal exam — a small, usually clinically irrelevant effect, but blood is best drawn before the exam rather than after

• Age itself — PSA rises gradually over a lifetime in men with entirely healthy prostates

One that goes the other direction and is easy to miss: 5-alpha reductase inhibitors — finasteride (Proscar, Propecia) and dutasteride (Avodart) — lower PSA by roughly half after about 6 to 12 months of use. If you take one of these for BPH or hair loss, your true PSA is approximately double what the lab reports. A "normal" 2.0 on finasteride may in fact represent a 4.0. Tell your urologist if you take either drug. The 2026 AUA/SUO guideline amendment added new material on exactly this point.

Before your PSA test: avoid ejaculation and vigorous cycling for 48 hours, and postpone testing if you currently have a urinary infection or are being treated for prostatitis.

Does a high PSA mean I have prostate cancer?

No. Most men with a raised PSA do not have prostate cancer. In the 4–10 ng/mL range, roughly two-thirds of men who go on to biopsy have no cancer found. A high PSA is a reason for further evaluation, not a diagnosis — and further evaluation today usually begins with additional testing rather than an immediate biopsy.

The reverse is also worth knowing: a normal PSA does not fully exclude cancer. Some high-grade tumors produce relatively little PSA. This is why PSA is interpreted alongside your risk factors, exam findings, and — when indicated — imaging.

What happens after an elevated PSA result? The step-by-step workup

An elevated PSA does not go straight to biopsy. The current pathway adds several filtering steps first, each designed to answer whether a biopsy is genuinely necessary. Roughly speaking:

Step 1 — Confirm the result. PSA fluctuates. A repeat test several weeks later, after excluding infection and avoiding the activities above, resolves a meaningful proportion of elevated results on its own. If there is any sign of prostatitis or UTI, that gets treated first and PSA is rechecked afterward.

Step 2 — Review your history and examine. Prostate size, medications (especially 5-ARIs), symptoms, family history, ethnicity, and prior PSA values all change how a given number should be read. A digital rectal exam may be performed as part of the assessment; it is a complement to PSA, not a substitute for it, and it is no longer recommended as a standalone screening test.

Step 3 — Refine the number. Several derivatives sharpen a borderline PSA:

• PSA density — PSA divided by prostate volume. A large prostate legitimately produces more PSA; density corrects for that. Values above roughly 0.15 raise concern.

• Free PSA percentage — the proportion of unbound PSA. Lower percentages (under about 10–15%) lean toward cancer; higher (over about 25%) lean toward benign causes. Most useful in the 4–10 range.

• PSA velocity — the rate of change over time. A steadily climbing PSA carries different weight than one that is stable and merely above a cutoff. Velocity is a useful signal, but it is not reliable enough to serve as a sole trigger for biopsy.

Step 4 — Consider a secondary biomarker. Blood and urine tests including the 4Kscore, Prostate Health Index (phi), MyProstateScore 2.0, ExoDx, and SelectMDx estimate the probability that a clinically significant cancer is present. These are most valuable in genuinely ambiguous cases. Guidelines advise against using them in men already assessed as low risk.

Step 5 — Multiparametric MRI. This is the most important change in prostate evaluation in a generation. An mpMRI images the gland before any biopsy and scores suspicious areas on the PI-RADS scale from 1 to 5. A reassuring MRI can support continued monitoring instead of biopsy in appropriately selected men. A suspicious one shows precisely where to sample. The 2026 AUA/SUO amendment strengthened its guidance on using MRI before an initial biopsy.

Step 6 — Targeted biopsy, only if indicated. When a biopsy is warranted, an MRI-fusion biopsy overlays MRI images onto live ultrasound so the suspicious lesion is sampled directly rather than blindly. The transperineal approach — through the skin rather than through the rectal wall — substantially reduces infection risk and reaches anterior tumors more reliably.

Step 7 — Results and plan. If no cancer is found, you move to a monitoring schedule. If cancer is found, the pathology report’s Grade Group and your PSA and imaging determine your risk category — and for many men with low-risk disease, the right next step is active surveillance rather than immediate treatment. Understanding your diagnosis →

When should I have a PSA test?

Guidelines vary, and the honest answer is that PSA screening involves a genuine tradeoff worth discussing rather than a single universal rule.

American Urological Association / SUO (2026 amendment):

• Baseline PSA at ages 45–50 for men at average risk, after a shared decision-making conversation

• Begin at ages 40–45 for men at higher risk — Black ancestry, a known germline mutation such as BRCA2, or a strong family history

• Screen roughly every 2 to 4 years between ages 50 and 69, personalized to your baseline result and health

• Continue past 70 selectively, based on health and prior values rather than age alone

U.S. Preventive Services Task Force (2018, update in progress): men aged 55–69 should make an individual decision in consultation with their clinician; routine screening is not recommended for men 70 and older.

American Cancer Society: informed decision-making discussion at 50 for average risk, 45 for high risk, 40 for men with multiple affected first-degree relatives.

Dr. Samadi’s clinical approach: based on his experience, Dr. Samadi favors an earlier baseline — typically at age 40 — with regular follow-up thereafter, particularly for men with risk factors. A baseline in your forties establishes your personal trajectory, which makes later results far easier to interpret. This is a more proactive posture than some guidelines take, and it is offered as one clinician’s judgment rather than as a consensus recommendation. It is worth discussing against your own risk profile.

Why choose Dr. Samadi for PSA evaluation

• Board-certified urologist and fellowship-trained urologic oncologist, focused specifically on prostate disease

• Complete workup in one place — PSA interpretation, secondary biomarkers, MRI coordination, and MRI-fusion biopsy when needed

• Second opinions welcome, including review of outside PSA results, MRI, and pathology

• Midtown Manhattan location at 485 Madison Avenue, convenient to Grand Central and midtown offices

• Direct physician contact rather than routing through layers of staff

We accept most major insurance plans. Our team will verify your specific coverage before your visit — call (212) 365-5000 to confirm.

Schedule an evaluation

If your PSA came back elevated, the next step is a structured evaluation to determine why. Dr. David Samadi and the team at Prostate Cancer 911 provide comprehensive PSA workup in Midtown Manhattan.

Request an Appointment

Office: 485 Madison Avenue, 21st Floor, New York, NY 10022 Phone: (212) 365-5000 Hours: [insert hours]

Sources

• American Urological Association / Society of Urologic Oncology. Early Detection of Prostate Cancer Guideline, 2026 amendment.

• National Cancer Institute. Prostate-Specific Antigen (PSA) Test fact sheet.

• Oesterling JE, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA.

• National Comprehensive Cancer Network. Prostate Cancer Early Detection, v1.2026.

This page provides general medical information and is not a substitute for individualized medical advice. Discuss your PSA results with a qualified physician.